Hard to meet May 1 deadline to withdraw from Afghanistan: Biden

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. WASHINGTON: United States President Joe Biden on Thursday (local time) said it is going to be hard to meet the May 1 deadline to pull out US troops from Afghanistan as per the deal made during the Donald Trump administration. Speaking at his first press conference since taking office, Biden said that, "It is gonna be hard to meet the May 1 deadline. In terms of tactical reason....it is hard to get those troops out. We have been meeting with our allies, those who also have troops in Afghanistan. If we leave we will do it in a safe and orderly way. We are in consultations with our allies and partners on how to proceed." "It is not my intention to stay there for a long time. But the question is how and under what circumstances do we meet that agreement that was made by (former) President Trump," Biden said when asked about exit of US troops from Afghanistan. Lastly, Biden said, "We (US) will leave (Afghanistan), the question is when we will leave." Since coming to power the Biden administration has made it clear that it is not willing to let the Taliban have its way as the price for ending the war in Afghanistan amid reports of al Qaeda gaining strength in the country. On February 29, 2020, the US and the Taliban movement signed a peace deal in Doha, Qatar, stipulating a gradual withdrawal of US troops as well as the beginning of intra-Afghan negotiations and prisoner exchanges. The talks were delayed multiple times until the Afghan government and the Taliban managed to agree on the prisoner exchange process as reported by Sputnik. To keep reading about Hard to meet May 1 deadline to withdraw from Afghanistan: Biden, Click on the link. Seoul, Korea
http://dlvr.it/RwP1mX

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

Coronavirus Hasn't Diminished Tech Stocks' Allure

Image
FYI: By Caitlin McCabe Caitlin McCabe The Wall Street Journal Biography caitlin.mccabe@wsj.com Updated April 20, 2020 6:14 pm ET The FANG trade hasn’t lost its bite. Big technology stocks are again charging to new heights and propelling the broader stock market, which is swiftly rebounding after a punishing selloff. The NYSE FANG+ index—which comprises Facebook Inc., FB -0.56% Amazon.com Inc., AMZN 0.78% Netflix Inc. NFLX 3.44% and Google parent Alphabet Inc., GOOG -1.30% along with Apple Inc., AAPL -2.08% Twitter Inc., Tesla Inc., TSLA -1.00% Nvidia Corp. NVDA -1.80% and the Chinese behemoths Alibaba Group Holding Ltd. and Baidu Inc. —is up 11% year-to-date after a dramatic rally last week. The four FANG stocks added $251 billion in market value last week, their biggest gain on record dating to Facebook’s 2012 initial public offering. The S&P 500, in comparison, is down 13% in 2020 but has r
Read more

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. SHANGHAI, March 28, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail to respond to the standard therapy has met the primary endpoint. Henlius plans to file a New Drug Application (NDA) to the National Drug Products Administration (NMPA) for the treatment of MSI-H solid tumours based on the results from the Phase 2 trial of HLX10, which will be presented at upcoming medical conferences. Professor Shukui Qin of No.81 Hospital of People's Liberation Army and Professor Jin Li of Shanghai East Hospital affiliated to Shang
Read more